RJFSA
HQL

Raymond James Financial Services Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Raymond James Financial Services Advisors’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.55M Buy
168,876
+7,189
+4% +$109K ﹤0.01% 1607
2024
Q2 		$2.29M Buy
161,687
+3,598
+2% +$48.7K ﹤0.01% 1582
2024
Q1 		$2.15M Buy
158,089
+27,012
+21% +$374K ﹤0.01% 1602
2023
Q4 		$1.76M Buy
131,077
+84,813
+183% +$1.04M ﹤0.01% 1641
2023
Q3 		$577K Sell
46,264
-15,439
-25% -$203K ﹤0.01% 2239
2023
Q2 		$835K Sell
61,703
-4,954
-7% -$68.3K ﹤0.01% 2027
2023
Q1 		$929K Buy
66,657
+3,146
+5% +$45K ﹤0.01% 1944
2022
Q4 		$902K Sell
63,511
-5,960
-9% -$86.3K ﹤0.01% 1904
2022
Q3 		$949K Sell
69,471
-3,822
-5% -$57.1K ﹤0.01% 1840
2022
Q2 		$1.04M Sell
73,293
-6,379
-8% -$96.4K ﹤0.01% 1804
2022
Q1 		$1.32M Buy
79,672
+13,324
+20% +$229K ﹤0.01% 1765
2021
Q4 		$1.28M Sell
66,348
-12,705
-16% -$256K ﹤0.01% 1823
2021
Q3 		$1.64M Buy
79,053
+10,574
+15% +$226K ﹤0.01% 1614
2021
Q2 		$1.47M Buy
68,479
+14,489
+27% +$292K ﹤0.01% 1684
2021
Q1 		$1.06M Buy
53,990
+6,375
+13% +$131K ﹤0.01% 1815
2020
Q4 		$940K Buy
47,615
+3,393
+8% +$62.7K ﹤0.01% 1739
2020
Q3 		$777K Buy
44,222
+4,932
+13% +$88.3K ﹤0.01% 1703
2020
Q2 		$706K Sell
39,290
-2,892
-7% -$49.6K ﹤0.01% 1702
2020
Q1 		$632K Sell
42,182
-9,680
-19% -$158K ﹤0.01% 1425
2019
Q4 		$904K Buy
51,862
+7,531
+17% +$124K ﹤0.01% 1591
2019
Q3 		$669K Buy
44,331
+159
+0.4% +$2.55K ﹤0.01% 1715
2019
Q2 		$744K Buy
44,172
+1,342
+3% +$22.1K ﹤0.01% 1665
2019
Q1 		$734K Sell
42,830
-4,448
-9% -$76.8K ﹤0.01% 1643
2018
Q4 		$714K Buy
47,278
+29,267
+162% +$515K ﹤0.01% 1450
2018
Q3 		$368K Sell
18,011
-949
-5% -$18.9K ﹤0.01% 2139
2018
Q2 		$356K Sell
18,960
-57
-0.3% -$1.07K ﹤0.01% 2116
2018
Q1 		$365K Sell
19,017
-124
-0.6% -$2.48K ﹤0.01% 1925
2017
Q4 		$376K Buy
19,141
+1,409
+8% +$28.2K ﹤0.01% 1880
2017
Q3 		$381K Buy
17,732
+6,345
+56% +$135K ﹤0.01% 1883
2017
Q2 		$237K Sell
11,387
-3,139
-22% -$63.4K ﹤0.01% 2105
2017
Q1 		$282K Sell
14,526
-2,513
-15% -$46.6K ﹤0.01% 1934
2016
Q4 		$289K Buy
17,039
+1,557
+10% +$27.3K ﹤0.01% 1822
2016
Q3 		$290K Buy
15,482
+1,656
+12% +$31.2K ﹤0.01% 1806
2016
Q2 		$238K Sell
13,826
-393
-3% -$7.25K ﹤0.01% 1875
2016
Q1 		$255K Buy
14,219
+697
+5% +$12.7K ﹤0.01% 1638
2015
Q4 		$320K Buy
13,522
+665
+5% +$16.5K ﹤0.01% 1391
2015
Q3 		$289K Buy
+12,857
New +$360K ﹤0.01% 1242

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
AIA
Absolute Investment Advisers Rosemary Beach, Florida $852M AUM 0.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Raymond James Financial Services Advisors's HQL Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its abrdn Life Sciences Investors (HQL) stake by 4.4% in Q3 2024, buying an estimated $109K and bringing the position to 168,876 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

Raymond James Financial Services Advisors first reported a position in HQL in Q3 2015 and has held it in 37 quarters since. 74 funds tracked by Wall St. Rank hold HQL as of Q3 2024.

  • Raymond James Financial Services Advisors held 168,876 shares of abrdn Life Sciences Investors worth $2.55M as of Q3 2024.
  • Raymond James Financial Services Advisors bought 7,189 abrdn Life Sciences Investors shares in Q3 2024, an estimated $109K.
  • abrdn Life Sciences Investors made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1607 holding.
  • Raymond James Financial Services Advisors first reported a position in abrdn Life Sciences Investors in Q3 2015 and has held it in 37 quarters since.
  • 74 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.